María Teresa Cibeira

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva, Norma C. Gutiérrez, Laura Rosiñol et al. · Blood · 2011 · 304 citations · Full text

Medicine, Hematology, Oncology +17

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

María Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin et al. · Blood · 2011 · 288 citations · Full text

Medicine, Hematology, Surgery +16

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael Wang, Meletios Α. Dimopoulos, Christine Chen et al. · Blood · 2008 · 175 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf et al. · Journal of Clinical Oncology · 2020 · 146 citations · Full text

Medicine, Oncology, Pharmacology +14